Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 25, 2026

FormFactor and Copart have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
FormFactor and Copart have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – March 25, 2026 – Zacks Equity Research shares FormFactor FORM as the Bull of the Day and Copart CPRT as the Bear of the Day…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Electronics - Semiconductors industry group is expected to outperform the market over the next 3 to 6 months

    60% confidence
  • As silicon photonics matures and moves to high-volume production, FormFactor expects its leadership position in combined electrical and optical testing to illuminate a new growth path in the future

    60% confidence
  • The top 50% of Zacks Ranked Industries outperforms the bottom 50% by a factor of more than 2 to 1

    60% confidence
  • FormFactor is benefiting from robust growth in high-bandwidth memory (HBM) driven by the rapid adoption of generative AI and high-performance computing

    60% confidence
  • Approximately half of a stock's price appreciation is due to its industry grouping based on historical research studies

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com